Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immune Modulation in Metastatic Melanoma Treated With Nivolumab +/- Ipilimumab
NCT03225365Completed
- Sponsor
- Hospices Civils de Lyon
- Start
- Oct 2019
- Primary completion
- Jun 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Open-label trial of nivolumab in melanoma (2 arms), sponsored by Hospices Civils de Lyon. Primary endpoints: Change description of biological characteristics of immune cells of the blood by immunomonitoring at 53 weeks and Change in the immune response by skin biopsy at 53 weeks. Started Oct 2019; status: completed.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT03225365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03225365.